Reuters logo
BRIEF-Syndax Pharmaceuticals says ‍expands pipeline with exclusive worldwide license to Allergan's portfolio of Menin-MLL inhibitors​
October 17, 2017 / 12:13 PM / a month ago

BRIEF-Syndax Pharmaceuticals says ‍expands pipeline with exclusive worldwide license to Allergan's portfolio of Menin-MLL inhibitors​

Oct 17 (Reuters) - Syndax Pharmaceuticals Inc:

* Syndax Pharmaceuticals Inc - ‍expands pipeline with exclusive worldwide license to Allergan’s portfolio of Menin-MLL inhibitors​

* Syndax Pharmaceuticals Inc - ‍ entered into an exclusive worldwide license agreement with Vitae Pharmaceuticals, inc., a subsidiary of Allergan PLC​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below